Company intelligence / Profile preview

Koligo Therapeutics

New Albany, Indiana, United Stateskoligo.net ↗

Ownership: Private
Development stage: Other

Overview

Koligo’s lead product, KYSLECEL™, was commercialized for the treatment of chronic and acute recurrent pancreatitis. The company developed a pipeline focused on autologous cell therapies using patients’ own pancreatic cells to treat pancreatic diseases, with additional research into type 1 diabetes. Their approach included proprietary methods to improve the viability and function of transplanted tissues, potentially leveraging advanced techniques like tissue engineering and bioprinting. In September 2020, Koligo was acquired by Orgenesis.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Autologous cell therapy (using patients' own cells)Islet cell therapyTissue engineering/3D bioprinting (platform technology)
Industry: Biotech

Beyond the preview

Go deeper on Koligo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Koligo Therapeutics.